Cancer in migrant populations: evidence from a regional oncology network
Elisabetta Coppola(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), S. Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Chiara D’Alessio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Vincenzo Montesarchio(CTO Hospital), Davide D’Errico(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Bruno Marra(University of Campania "Luigi Vanvitelli"), Tania Losanno(Institute of Food Science), Michele Orditura(University of Campania "Luigi Vanvitelli"), Antonio Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annarita Roscigno(University of Salerno), Paolo Chiodini(University of Campania "Luigi Vanvitelli"), Rosanna Ortolani(Regione Campania), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Stefano Pepe(University of Naples Federico II), Gaetano Facchini(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Cesare Gridelli, Rodolfo Cangiano, Luigi Leo, Filomena Sibilio(Accademia di Belle Arti di Napoli), Bruno Daniele, Alfredo Budillon(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Laura Arenare(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Palmieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberto Bianco(University of Naples Federico II), Elena Fossi, Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gabriele Calvanese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer
|Journal of Clinical Oncology|2015|795